Outcome of Board Meeting held today i.e. Friday, May 29, 2026 wherein the Board inter-alia considered and approved Audited Financial results and statements for the Financial Year ended ....
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's Board approved audited standalone and consolidated financial results for FY ended March 31, 2026. Revenue from operations declined to Rs. 1,05,507 lakhs from Rs. 1,20,009 lakhs in the prior year (approximately 12% decline). Profit after tax fell to Rs. 26,327 lakhs from Rs. 37,296 lakhs, representing roughly 29.5% decline. EBITDA margin compressed from ~40% to ~32%. The company recognized an exceptional charge of Rs. 327.54 lakhs due to new labour codes. The Board recommended dividend of Rs. 7.55 per equity share. Statutory auditors BSR & Co. LLP issued an unmodified (clean) opinion. Mrs. Ekta Gupta was appointed as Additional Independent Director, and new internal and cost auditors were appointed for FY 2026-27. Celliimune Biotech became a wholly-owned subsidiary post year-end.
Revenue and profit declines signal headwinds for the biotech company. EBITDA margin compression indicates cost pressures. However, clean audit opinion and dividend payment demonstrate financial stability despite challenging conditions.